



## Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

October 23, 2023

SAN DIEGO--(BUSINESS WIRE)--Oct. 23, 2023-- Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor and scientific conferences.

### 11<sup>th</sup> International mRNA Health Conference (Presentation)

- Wednesday, November 1, 2023 (10:42 a.m. CET)

### Guggenheim's 5<sup>th</sup> Annual Inflammation, Neurology & Immunology Conference (Fireside Chat)

- Tuesday, November 7, 2023 (9:10 a.m. ET)

### Piper Sandler 35<sup>th</sup> Annual Healthcare Conference (Fireside chat)

- Tuesday, November 28, 2023 (TBD)

Webcast links can be found under Investor Relations/Events section of Arcturus' [website](#).

### About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR<sup>®</sup> lipid-mediated delivery, (ii) STARR<sup>®</sup> mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. The Company has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China, and other countries). For more information, visit [www.ArcturusRx.com](http://www.ArcturusRx.com). In addition, please connect with us on [Twitter](#) and [LinkedIn](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231023615523/en/): <https://www.businesswire.com/news/home/20231023615523/en/>

### IR and Media Contacts

Arcturus Therapeutics  
Neda Safarzadeh  
VP, Head of IR/PR/Marketing  
(858) 900-2682  
[IR@ArcturusRx.com](mailto:IR@ArcturusRx.com)

Kendall Investor Relations  
Carlo Tanzi, Ph.D.  
(617) 914-0008  
[ctanzi@kendallir.com](mailto:ctanzi@kendallir.com)

Source: Arcturus Therapeutics Holdings Inc.